On Oct. 25 Northwest Biotherapeutics, Inc (OTC:NWBO) announced in a press release the initiation of Factual Stock Report coverage in conjunction with Standard & Poor’s Market Access Program.
The press release contained a link to the first report. NWBO scored 75 in Standard & Poor’s Relative Strength Rank. The mark is positive and indicates that NWBO has performed well compared with other companies on a rolling 13-week basis.[BANNER]
The report is mostly positive, but the market is still uncertain what to do with NWBO. Yesterday, NWBO dropped 6.14%, closing at $0.52 on nearly 500 thousand shares.
The previous two sessions NWBO managed to close in the green, following a loss and a gain before that.
There is a lot of potential for NWBO, both on the business side and on the stock market, but it may take something more concrete for the stock to make a stable move or run.
